Search Results

Safety and Efficacy of LimFlow’s pDVA System Evaluated in PROMISE I Trial

November 6, 2020—Daniel Clair, MD, presented findings from the multicenter PROMISE I trial of the first human use in the United States of the LimFlow system (LimFlow SA), a purpose-built percutaneous deep vein arterialization (pDVA) device for the treatment of no-option chronic limb-threatening ischemia (CLTI) patients.

LimFlow Deep Vein Arterialization System to Treat CLTI Evaluated in 2-Year PROMISE I Data

October 6, 2021—Daniel Clair, MD, presented 2-year results from the PROMISE I trial, which is evaluating the LimFlow system (LimFlow SA) for creating deep vein arterialization in the treatment of patients with severe, unreconstructable chronic limb-threatening ischemia (CLTI).

Nine-Month ORION Data Support Boston Scientific's Epic Stent to Treat Iliac Disease

January 16, 2012—Boston Scientific Corporation (Natick, MA) announced that Principal Investigator Daniel Clair, MD, presented 9-month clinical endpoint data from the company's ORION trial at the International Symposium on Endovascular Therapy (ISET) in Miami Beach, Florida.

PROMISE II Trial Evaluates TADV With Inari’s LimFlow System

November 5, 2024—Two-year outcomes from the PROMISE II trial assessed transcatheter arterialization of the deep veins (TADV) using the LimFlow System (Inari Medical).

Endospan's Nexus Arch Branch Stent Graft System Studied at 2 Years

November 5, 2019—VIVA Physicians announced that 2-year results from a prospective, multicenter, premarket study composed of 25 patients (mean age, 73 years) treated with the Nexus aortic arch stent graft (Endospan) were presented by Daniel Clair, MD, in a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.

Six-Month Data From PROMISE I Presented for LimFlow System to Treat CLTI

November 6, 2019—LimFlow SA announced the presentation of positive 6-month data from the full patient cohort in the PROMISE I early feasibility study of the LimFlow percutaneous deep vein arterialization system.

ORION 12-Month Data Support Boston Scientific's Epic Stent for Iliac Artery Disease

October 23, 2012—Boston Scientific Corporation (Natick, MA) announced that 12-month clinical endpoint data from the ORION trial demonstrated the safety and effectiveness of the Epic self-expanding nitinol stent system in patients with obstructed iliac arteries.

FastWave Names Leadership for Pivotal Trial of Artero Electric IVL System

September 30, 2025—FastWave Medical, a developer of intravascular lithotripsy (IVL), announced the appointment of the principal investigators and steering committee for the upcoming United States investigational device exemption pivotal trial of the company’s Artero peripheral electric IVL system.

LimFlow System for TADV in CLTI Evaluated at 1 Year in PROMISE II Pivotal Trial

October 31, 2023—The 1-year results of the multicenter PROMISE II pivotal trial of the purpose-built LimFlow system (LimFlow, Inc.) for transcatheter arterialization of deep veins (TADV) evaluated the device in the treatment of patients with no-option chronic limb-threatening ischemia (CLTI) patients.

Boston Scientific Completes Enrollment in ORION Trial of Epic Stent to Treat Iliac Disease

January 10, 2011—Boston Scientific Corporation (Natick, MA) announced the completion of enrollment in the ORION clinical trial, which is designed to evaluate the company's Epic self-expanding nitinol stent system for the treatment of iliac artery disease.

LimFlow System’s 6-Month Outcomes Presented From the PROMISE II US Pivotal Trial

November 4, 2022—Six-month results from the PROMISE II United States pivotal trial of transcatheter arterialization of the deep veins with the LimFlow system (LimFlow, Inc.) showed that outcomes were better than expected and reproducible, and that the study’s “no-option” patient population can significantly benefit from this procedure.